Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020)
Attributed to:
ISARIC - Coronavirus Clinical Characterisation Consortium (ISARIC-4C)
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)31604-4
PubMed Identifier: 32702298
Publication URI: http://europepmc.org/abstract/MED/32702298
Type: Journal Article/Review
Parent Publication: The Lancet
Issue: 10249
ISSN: 0140-6736